The role of microbiota and its modulation in colonic diverticular disease.
diverticular disease
diverticulosis
fecal microbiota transplantation
fiber
mesalazine
metabolome
microbiota
probiotics
rifaximin
symptomatic uncomplicated diverticular disease
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
06
05
2023
received:
21
03
2023
accepted:
14
05
2023
medline:
1
12
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
ppublish
Résumé
Diverticular disease (DD) is a common condition in Western countries. The role of microbiota in the pathogenesis of DD and its related symptoms has been frequently postulated since most complications of this disease are bacteria-driven and most therapies rely on microbiota modulation. Preliminary data showed fecal microbial imbalance in patients with DD, particularly when symptomatic, with an increase of pro-inflammatory and potentially pathogenetic bacteria. In addition, bacterial metabolic markers can mirror specific pathways of the disease and may be even used for monitoring treatment effects. All treatments currently suggested for DD can affect microbiota structure and metabolome compositions. Sparse evidence is available linking gut microbiota perturbations, diverticular disease pathophysiology, and symptom development. We aimed to summarize the available knowledge on gut microbiota evaluation in diverticular disease, with a focus on symptomatic uncomplicated DD, and the relative treatment strategies.
Sections du résumé
BACKGROUND
BACKGROUND
Diverticular disease (DD) is a common condition in Western countries. The role of microbiota in the pathogenesis of DD and its related symptoms has been frequently postulated since most complications of this disease are bacteria-driven and most therapies rely on microbiota modulation. Preliminary data showed fecal microbial imbalance in patients with DD, particularly when symptomatic, with an increase of pro-inflammatory and potentially pathogenetic bacteria. In addition, bacterial metabolic markers can mirror specific pathways of the disease and may be even used for monitoring treatment effects. All treatments currently suggested for DD can affect microbiota structure and metabolome compositions.
PURPOSE
OBJECTIVE
Sparse evidence is available linking gut microbiota perturbations, diverticular disease pathophysiology, and symptom development. We aimed to summarize the available knowledge on gut microbiota evaluation in diverticular disease, with a focus on symptomatic uncomplicated DD, and the relative treatment strategies.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14615Subventions
Organisme : Fondazione Carisbo
Organisme : Fondazione del Monte di Bologna e Ravenna
Organisme : Horizon 2020 Framework Programme
Organisme : Italian Ministry of Health
Informations de copyright
© 2023 The Authors. Neurogastroenterology & Motility published by John Wiley & Sons Ltd.
Références
Cuomo R, Barbara G, Pace F, et al. Italian consensus conference for colonic diverticulosis and diverticular disease. United Eur Gastroenterol J. 2014;2:413-442.
Peery AF, Sandler RS. Diverticular disease: reconsidering conventional wisdom. Clin Gastroenterol Hepatol. 2013;11:1532-1537.
Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology. 2009;136:741-754.
Schieffer KM, Kline BP, Yochum GS, Koltun WA. Pathophysiology of diverticular disease. Expert Rev Gastroenterol Hepatol. 2018;12:683-692.
Rezapour M, Ali S, Stollman N. Diverticular disease: an update on pathogenesis and management. Gut Liver. 2018;12:125-132.
Slack WW. The anatomy, pathology, and some clinical features of diverticulitis of the colon. Br J Surg. 1962;50:185-190.
Tursi A, Papa A, Danese S. Review article: The pathophysiology and medical management of diverticulosis and diverticular disease of the colon. Alimentary Pharmacol Therapeut. 2015;42:664-684.
Spiller RC. Changing views on diverticular disease: impact of aging, obesity, diet, and microbiota. Neurogastroenterol Motil. 2015;27:305-312.
Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microb Ecol Heal Dis. 2015;26:26.
Di Biase AR, Marasco G, Ravaioli F, et al. Gut microbiota signatures and clinical manifestations in celiac disease children at onset: a pilot study. J Gastroenterol Hepatol. 2020;36:446-454. doi:10.1111/jgh.15183
Barbara G, Grover M, Bercik P, et al. Rome foundation working team report on post-infection irritable bowel syndrome. Gastroenterology. 2019;156:46-58.e7.
Nistal E, Caminero A, Herrán AR, et al. Differences of small intestinal bacteria populations in adults and children with/without celiac disease: effect of age, gluten diet, and disease. Inflamm Bowel Dis. 2012;18:649-656.
Marasco G, Lenti MV, Cremon C, et al. Implications of SARS-CoV-2 infection for neurogastroenterology. Neurogastroenterol Motil. 2021;33:e14104.
Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157:121-141.
Cerf-Bensussan N, Gaboriau-Routhiau V. The immune system and the gut microbiota: friends or foes? Nat Rev Immunol. 2010;10:735-744.
Manson JM, Rauch M, Gilmore MS. The commensal microbiology of the gastrointestinal tract. Adv Exp Med Biol. 2008;635:15-28.
Simreń M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62:159-176.
Marasco G, Colecchia A, Festi D. Dysbiosis in celiac disease patients with persistent symptoms on gluten-free diet: a condition similar to that present in irritable bowel syndrome patients? Am J Gastroenterol. 2015;110:598.
Scaioli E, Colecchia A, Marasco G, Schiumerini R, Festi D. Pathophysiology and therapeutic strategies for symptomatic uncomplicated diverticular disease of the colon. Dig Dis Sci. 2016;61:673-683.
Barbaro MR, Cremon C, Fuschi D, et al. Pathophysiology of diverticular disease: from diverticula formation to symptom generation. Int J Mol Sci. 2022;23:6698.
Barbara G, Scaioli E, Barbaro MR, et al. Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. Gut. 2017;66:1252-1261.
Scarpignato C, Barbara G, Lanas A, Strate LL. Management of colonic diverticular disease in the third millennium: highlights from a symposium held during the united European gastroenterology week 2017. Therap Adv Gastroenterol. 2018;11:175628481877130.
Ticinesi A, Nouvenne A, Corrente V, Tana C, Di Mario F, Meschi T. Diverticular disease: A gut microbiota perspective. J Gastrointestin Liver Dis. 2019;28:327-337.
Tamboli CP, Neut C, Desreumaux P, Colombel JF. Dysbiosis in inflammatory bowel disease. Gut. 2004;53:1-4.
Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nature Rev Gastroenterol Hepatol. 2019;16:690-704.
Van Rossen TM, Ooijevaar RE, Kuyvenhoven JP, et al. Microbiota composition and mucosal immunity in patients with asymptomatic diverticulosis and controls. PLoS One. 2021;16:e0256657.
Alexandersson BT, Hugerth LW, Hedin C, et al. Diverticulosis is not associated with altered gut microbiota nor is it predictive of future diverticulitis: a population-based colonoscopy study. Scand J Gastroenterol. 2023;1-8. doi:10.1080/00365521.2023.2194010
Lopetuso LR, Petito V, Graziani C, et al. Gut microbiota in health, diverticular disease, irritable bowel syndrome, and inflammatory bowel diseases: time for microbial marker of gastrointestinal disorders. Dig Dis. 2017;36:56-65.
Johnson EL, Heaver SL, Walters WA, Ley RE. Microbiome and metabolic disease: revisiting the bacterial phylum Bacteroidetes. J Mol Med. 2017;95:1-8.
Tursi A, Mastromarino P, Capobianco D, et al. Assessment of fecal microbiota and fecal metabolome in symptomatic uncomplicated diverticular disease of the colon. J Clin Gastroenterol. 2016;50:S9-S12.
Daniels L, Budding AE, de Korte N, et al. Fecal microbiome analysis as a diagnostic test for diverticulitis. Eur J Clin Microbiol Infect Dis. 2014;33:1927-1936.
Flint HJ, Scott KP, Louis P, et al. The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol. 2012;9:577-589.
Tursi A, Mastromarino P, Capobianco D, et al. Faecalibacterium prausnitzii is not decreased in symptomatic uncomplicated diverticular disease of the colon. Biosci Microbiota Food Heal. 2023;42:1-2.
Barbaro MR, Cremon C, Fuschi D, et al. Nerve fiber overgrowth in patients with symptomatic diverticular disease. Neurogastroenterol Motil. 2019;31:e13575.
Collado MC, Derrien M, Isolauri E, de Vos WM, Salminen S. Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl Environ Microbiol. 2007;73:7767-7770.
Earley H, Lennon G, Balfe Á, Coffey JC, Winter DC, O'Connell PR. The abundance of Akkermansia muciniphila and its relationship with sulphated colonic mucins in health and ulcerative colitis. Sci Rep. 2019;9:15683.
Marasco G, Di Biase AR, Schiumerini R, et al. Gut microbiota and celiac disease. Dig Dis Sci. 2016;61:1461-1472.
Swidsinski A, Dörffel Y, Loening-Baucke V, et al. Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum. Gut. 2011;60:34-40.
Zhang H, DiBaise JK, Zuccolo A, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA. 2009;106:2365-2370.
Png CW, Lindén SK, Gilshenan KS, et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol. 2010;105:2420-2428.
Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol. 2004;54:1469-1476.
Laghi L, Mastromarino P, Elisei W, et al. Impact of treatments on fecal microbiota and fecal metabolome in symptomatic uncomplicated diverticular disease of the colon: a pilot study. J Biol Regul Homeost Agents. 2018;32:1421-1432.
Kvasnovsky CL, Leong LEX, Choo JM, et al. Clinical and symptom scores are significantly correlated with fecal microbiota features in patients with symptomatic uncomplicated diverticular disease: a pilot study. Eur J Gastroenterol Hepatol. 2018;30:107-112.
Shin NR, Whon TW, Bae JW. Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 2015;33:496-503.
Lupp C, Robertson ML, Wickham ME, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host and Microbe. 2007;2:204. doi:10.1016/j.chom.2007.06.010
Reitano E, Francone E, Bona E, Follenzi A, Gentilli S. Gut microbiota association with diverticular disease pathogenesis and progression: a systematic review. Dig Dis Sci. 2022;1:1-9.
O'Grady MJ, Turner GA, Sulit A, Frizelle FA, Purcell R. Distinct changes in the colonic microbiome associated with acute diverticulitis. Colorectal Dis. 2022;24:1591-1601.
Clish CB. Metabolomics: an emerging but powerful tool for precision medicine. Mol Case Stud. 2015;1:a000588.
Tursi A, Mastromarino P, Capobianco D, et al. Urinary metabolic profiling and symptomatic uncomplicated diverticular disease of the colon. Clin Res Hepatol Gastroenterol. 2017;41:344-346.
Lees HJ, Swann JR, Wilson ID, Nicholson JK, Holmes E. Hippurate: the natural history of a mammalian-microbial cometabolite. J Proteome Res. 2013;12:1527-1546.
Bajaj JS, Jane Cox I, Betrapally NS, et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol. 2014;307:G951-G957.
Brahmachari S, Jana A, Pahan K. Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and Astroglial inflammatory responses. J Immunol. 2009;183:5917-5927.
Keszthelyi D, Troost FJ, Masclee AAM. Understanding the role of tryptophan and serotonin metabolism in gastrointestinal function. Neurogastroenterol Motil. 2009;21:1239-1249.
Slavin J. Fiber and prebiotics: mechanisms and health benefits. Nutrients. 2013;5:1417-1435.
Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334:105-108.
Makki K, Deehan EC, Walter J, Bäckhed F. The impact of dietary fiber on gut microbiota in host health and disease. Cell Host Microbe. 2018;23:705-715.
Myhrstad MCW, Tunsjø H, Charnock C, Telle-Hansen VH. Dietary fiber, gut microbiota, and metabolic regulation-current status in human randomized trials. Nutrients. 2020;12:859.
Burkitt DP, Walker ARP, Painter NS. Effect of dietary fibre on stools and transit-times, and its role IN the causation of disease. The Lancet. 1972;300:1408-1411.
Aune D, Sen A, Norat T, Riboli E. Dietary fibre intake and the risk of diverticular disease: a systematic review and meta-analysis of prospective studies. Eur J Nutr. 2020;59:421-432.
Crowe FL, Balkwill A, Cairns BJ, et al. Source of dietary fibre and diverticular disease incidence: a prospective study of UK women. Gut. 2014;63:1450-1456.
Song JH, Kim YS, Lee JH, et al. Clinical characteristics of colonic diverticulosis in Korea: a prospective study. Korean J Intern Med. 2010;25:140-146.
Peery AF, Barrett PR, Park D, et al. A high-fiber diet does not protect against asymptomatic diverticulosis. Gastroenterology. 2012;142:266-272.e1.
Peery AF, Sandler RS, Ahnen DJ, et al. Constipation and a low-fiber diet are not associated with diverticulosis. Clin Gastroenterol Hepatol. 2013;11:1622-1627.
Carabotti M, Annibale B, Severi C, Lahner E. Role of fiber in symptomatic uncomplicated diverticular disease: a systematic review. Nutrients. 2017;9:9.
Painter NS. The cause of diverticular disease of the colon, its symptoms and its complications. Review and hypothesis. J R Coll Surg Edinb. 1985;30:118-122.
Liu PH, Cao Y, Keeley BR, et al. Adherence to a healthy lifestyle is associated with a lower risk of diverticulitis among men. Am J Gastroenterol. 2017;112:1868-1876.
Eberhardt F, Crichton M, Dahl C, et al. Role of dietary fibre in older adults with asymptomatic (AS) or symptomatic uncomplicated diverticular disease (SUDD): systematic review and meta-analysis. Maturitas. 2019;130:57-67.
Ma W, Nguyen LH, Song M, et al. Intake of dietary fiber, fruits, and vegetables and risk of diverticulitis. Am J Gastroenterol. 2019;114:1531-1538.
Mahmood MW, Abraham-Nordling M, Håkansson N, Wolk A, Hjern F. High intake of dietary fibre from fruit and vegetables reduces the risk of hospitalisation for diverticular disease. Eur J Nutr. 2019;58:2393-2400.
Ünlü C, Daniels L, Vrouenraets BC, Boermeester MA. A systematic review of high-fibre dietary therapy in diverticular disease. Int J Colorectal Dis. 2012;27:419-427.
Andersen JC, Bundgaard L, Elbrønd H, Laurberg S, Walker LR, Støvring J. Danish national guidelines for treatment of diverticular disease. Dan Med J. 2012;59:C4453.
Murphy T, Hunt RH, Fried M, Krabshuis JH. World Gastroenterology Organisation Practice Guidelines: Diverticular Disease. World Gastroenterology Organisation; 2007.
Hill C, Guarner F, Reid G, et al. Expert consensus document: the international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506-514.
Lahner E, Annibale B. Probiotics and diverticular disease. J Clin Gastroenterol. 2016;50:S159-S160.
Marasco G, Cirota GG, Rossini B, et al. Probiotics, prebiotics and other dietary supplements for gut microbiota modulation in celiac disease patients. Nutrients. 2020;12:2674.
Fong W, Li Q, Yu J. Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer. Oncogene. 2020;39:4925-4943.
Alvarez CS, Badia J, Bosch M, Giménez R, Baldomà L. Outer membrane vesicles and soluble factors released by probiotic Escherichia coli nissle 1917 and commensal ECOR63 enhance barrier function by regulating expression of tight junction proteins in intestinal epithelial cells. Front Microbiol. 2016;7:7.
Barbaro MR, Fuschi D, Cremon C, et al. Escherichia coli Nissle 1917 restores epithelial permeability alterations induced by irritable bowel syndrome mediators. Neurogastroenterol Motil. 2018;e13388. doi:10.1111/nmo.13388
Barbara G, Barbaro MR, Fuschi D, et al. Inflammatory and microbiota-related regulation of the intestinal epithelial barrier. Front Nutr. 2021;8:8.
Tursi A, Scarpignato C, Strate LL, et al. Colonic diverticular disease. Nat Rev Dis Primers. 2020;6:20.
Lahner E, Esposito G, Zullo A, et al. High-fibre diet and Lactobacillus paracasei B21060 in symptomatic uncomplicated diverticular disease. World J Gastroenterol. 2012;18:5918-5924.
Annibale B, Maconi G, Lahner E, De Giorgi F, Cuomo R. Efficacy of Lactobacillus paracasei sub. Paracasei F19 on abdominal symptoms in patients with symptomatic uncomplicated diverticular disease: a pilot study. Minerva Gastroenterol Dietol. 2011;57(1):13-22.
Kvasnovsky CL, Bjarnason I, Donaldson AN, Sherwood RA, Papagrigoriadis S. A randomized double-blind placebo-controlled trial of a multi-strain probiotic in treatment of symptomatic uncomplicated diverticular disease. Inflammopharmacology. 2017;25:499-509.
Tursi A, Brandimarte G, Elisei W, et al. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease - a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther. 2013;38:741-751.
Stollman N, Magowan S, Shanahan F, Quigley EMM. A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. J Clin Gastroenterol. 2013;47:621-629.
Petruzziello C, Migneco A, Cardone S, et al. Supplementation with lactobacillus reuteri ATCC PTA 4659 in patients affected by acute uncomplicated diverticulitis: a randomized double-blind placebo controlled trial. Int J Colorectal Dis. 2019;34:1087-1094.
Lahner E, Bellisario C, Hassan C, Zullo A, Esposito G, Annibale B. Probiotics in the treatment of diverticular disease. A systematic review. J Gastrointestin Liver Dis. 2016;25:79-86.
Cuomo R, Barbara G, Annibale B. Rifaximin and diverticular disease: position paper of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis. 2017;49:595-603.
DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect. 2004;10:1009-1011.
Fodor AA, Pimentel M, Chey WD, et al. Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. Gut Microbes. 2019;10:22-33.
Humes DJ, Spiller RC. Review article: the pathogenesis and management of acute colonic diverticulitis. Aliment Pharmacol Ther. 2014;39:359-370.
Ponziani FR, Scaldaferri F, de Siena M, et al. Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment. Benef Microbes. 2020;11:519-525.
Ponziani FR, Zocco MA, D'Aversa F, Pompili M, Gasbarrini A. Eubiotic properties of rifaximin: disruption of the traditional concepts in gut microbiota modulation. World J Gastroenterol. 2017;23:4491-4499.
Tursi A, Scarpignato C, Brandimarte G, Di Mario F, Lanas A. Rifaximin for the management of colonic diverticular disease: far beyond a simple antibiotic. J Gastrointestin Liver Dis. 2018;27:351-355.
Bajaj JS, Barbara G, DuPont HL, Mearin F, Gasbarrini A, Tack J. New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. Dig Liver Dis. 2018;50:741-749.
Hirota A, Understanding S. The molecular mechanisms of Rifaximin in the treatment of gastrointestinal disorders - a focus on the modulation of host tissue function. Mini-Rev Med Chem. 2016;16:206-217.
Cianci R, Frosali S, Pagliari D, et al. Uncomplicated diverticular disease: innate and adaptive immunity in human gut mucosa before and after Rifaximin. J Immunol Res. 2014;2014:1-11.
Yang CQ, Guo XS, Ji L, et al. Rifaximin improves visceral hyperalgesia via TRPV1 by modulating intestinal Flora in the water avoidance stressed rat. Gastroenterol Res Pract. 2020;2020:1-9.
Frieri G, Pimpo MT, Scarpignato C. Management of colonic diverticular disease. Digestion. 2006;73:58-66.
D'Incà R, Pomerri F, Vettorato MG, et al. Interaction between rifaximin and dietary fibre in patients with diverticular disease. Aliment Pharmacol Ther. 2007;25:771-779.
Papi C, Ciaco A, Koch M, Capurso L. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther. 1995;9:33-39.
Di Mario F, Miraglia C, Cambiè G, et al. Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon. J Invest Med. 2019;67:767-770.
Latella G, Pimpo MT, Sottili S, et al. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis. 2003;18:55-62.
Colecchia A, Vestito A, Pasqui F, et al. Efficacy of long term cyclic administration of the poorly absorbed Rifaximin in symptomatic, uncomplicted colonic diverticular disease. World J Gastroenterol. 2007;13:264-269.
Bianchi M, Festa V, Moretti A, et al. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease. Aliment Pharmacol Ther. 2011;33:902-910.
Maconi G, Barbara G, Bosetti C, Cuomo R, Annibale B. Treatment of diverticular disease of the colon and prevention of acute diverticulitis: a systematic review. Dis Colon Rectum. 2011;54:1326-1338.
Festa V, Spila Alegiani S, Chiesara F, et al. Retrospective comparison of long-term ten-day/month rifaximin or mesalazine in prevention of relapse in acute diverticulitis. Eur Rev Med Pharmacol Sci. 2017;21:1397-1404.
De Vincentis A, Santonico M, Del Chierico F, et al. Gut microbiota and related electronic multisensorial system changes in subjects with symptomatic uncomplicated diverticular disease undergoing Rifaximin therapy. Front Med. 2021;8:655474.
Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol. 2012;5:113-123.
Hanauer SB. Inflammatory bowel disease. N Engl J Med. 1996;334:841-848.
Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Alimentary Pharmacol Therapeut. 2006;24:2-9.
Ben XM, Li J, Feng ZT, et al. Low level of galacto-oligosaccharide in infant formula stimulates growth of intestinal Bifidobacteria and lactobacilli. World J Gastroenterol. 2008;14:6564-6568.
Xue L, Huang Z, Zhou X, Chen W. The possible effects of mesalazine on the intestinal microbiota. Alimentary Pharmacol Therapeut. 2012;36:813-814.
Khare V, Krnjic A, Frick A, et al. Mesalamine and azathioprine modulate junctional complexes and restore epithelial barrier function in intestinal inflammation. Sci Rep. 2019;9:9.
Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Get your full text copy in PDF #11659|Medical Science Monitor.
Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol. 2006;40:312-316.
Kruis W, Kardalinos V, Eisenbach T, et al. Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence. Aliment Pharmacol Ther. 2017;46:282-291.
Comparato G, Fanigliulo L, Cavallaro LG, et al. Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. Dig Dis Sci. 2007;52:2934-2941.
Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. Dig Dis Sci. 2007;52:671-674.
Picchio M, Elisei W, Brandimarte G, et al. Mesalazine for the treatment of symptomatic uncomplicated diverticular disease of the colon and for primary prevention of diverticulitis: a systematic review of randomized clinical trials. J Clin Gastroenterol. 2016;50:S64-S69.
Picchio M, Elisei W, Tursi A. Mesalazine to treat symptomatic uncomplicated diverticular disease and to prevent acute diverticulitis occurrence. A systematic review with meta-analysis of randomized, placebo-controlled trials. J Gastrointestin Liver Dis. 2018;27:291-297.
Khan RMA, Ali B, Hajibandeh S, Hajibandeh S. Effect of mesalazine on recurrence of diverticulitis in patients with symptomatic uncomplicated diverticular disease: a meta-analysis with trial sequential analysis of randomized controlled trials. Colorectal Dis. 2018;20:469-478.
Tursi A, Brandimarte G, Daffinà R. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig Liver Dis. 2002;34:510-515.
Raskin JB, Kamm MA, Jamal MM, et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology. 2014;147:793-802.
Gatta L, Di Mario F, Curlo M, et al. Long-term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease. Intern Emerg Med. 2012;7:133-137.
Kim KO, Gluck M. Fecal microbiota transplantation: an update on clinical practice. Clin Endoscopy. 2019;52:137-143.
Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312:1772-1778.
Cammarota G, Ianiro G, Tilg H, et al. European Consensus Conference on Faecal Microbiota Transplantation in Clinical Practice. Gut. 2017;66:569-580.
Shankar V, Hamilton MJ, Khoruts A, et al. Species and genus level resolution analysis of gut microbiota in Clostridium difficile patients following fecal microbiota transplantation. Microbiome. 2014;2:2.
Allegretti JR, Mullish BH, Kelly C, Fischer M. The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications. Lancet. 2019;394:420-431.
Weingarden AR, Chen C, Bobr A, et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol. 2014;306:306-G319.
Meyer DC, Hill SS, Bebinger DM, et al. Resolution of multiply recurrent and multifocal diverticulitis after fecal microbiota transplantation. Tech Coloproctol. 2020;24:971-975.
Mandalia A, Kraft CS, Dhere T. Diverticulitis after fecal microbiota transplant for C. difficile infection. Am J Gastroenterol. 2014;109:1956-1957.
Schieffer KM, Sabey K, Wright JR, et al. The microbial ecosystem distinguishes chronically diseased tissue from adjacent tissue in the sigmoid colon of chronic, recurrent diverticulitis patients. Sci Rep. 2017;7:8467.
Jones RB, Fodor AA, Peery AF, et al. An aberrant microbiota is not strongly associated with incidental colonic diverticulosis. Sci Rep. 2018;8:4951.
Dahl C, Crichton M, Jenkins J, et al. Evidence for dietary fibre modification in the recovery and prevention of reoccurrence of acute, uncomplicated diverticulitis: a systematic literature review. Nutrients. 2018;10:137.
Papi C, Ciaco A, Koch M, Capurso L. Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular disease study group. Ital J Gastroenterol. 1992;24:452-456.
Parente F, Bargiggia S, Prada A, et al. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double-blind placebo-controlled study of 24-month duration. Int J Colorectal Dis. 2013;28:1423-1431.